Terms: = Liver cancer AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734 AND Prognosis
12487 results:
1. Comprehensive Analysis of the Immunosuppressive Function of Regulatory T Cells in Human Hepatocellular Carcinoma Tissues.
Ge J; Chen J; Shen Q; Zheng X; Chen X; Shi L; Chen L; Xu B
Cancer Control; 2024; 31():10732748241251580. PubMed ID: 38712609
[TBL] [Abstract] [Full Text] [Related]
2. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract] [Full Text] [Related]
3. Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
[TBL] [Abstract] [Full Text] [Related]
5. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
6. Construction and validation of "WCH-nomogram" for predicting the prognosis after resection of colorectal liver metastases.
Jiang C; Liu W; Jin Z; Lan L; Xu L; Du A; Peng S; Zeng Y; Wang H; Liao M; Zhou J
Cancer Med; 2024 May; 13(9):e7222. PubMed ID: 38698687
[TBL] [Abstract] [Full Text] [Related]
7. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract] [Full Text] [Related]
8. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract] [Full Text] [Related]
9.
Waziri P; Auta R; Imam MU; Chindo BA; Ladan Z; Mohammed Z; Wayah S; Mohammed J; Tahir MI; Ahmad AE; Alhassan Y; Tyoapine D; Agbaji AS
J Evid Based Integr Med; 2024; 29():2515690X241251558. PubMed ID: 38689490
[TBL] [Abstract] [Full Text] [Related]
10. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
11. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection.
Rao L; Xu P; Zhang G; Zu R; Luo Y; Zhang K; Yang Y; Wang D; He S; Luo H; Ye B
BMC Cancer; 2024 Apr; 24(1):543. PubMed ID: 38684978
[TBL] [Abstract] [Full Text] [Related]
13. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract] [Full Text] [Related]
14. Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study.
Zhang X; Zhu X; Zhong J; Zhao Y; Zhang X; Zhang W; Ye F; Yang C; Xue J; Xiong R; Wang J; Shen S; Pan Y; Li D; Song T; Bi X; Sun H; Xiang B; Gu S; Wen T; Lu S; Chen Y; Yin T; Liu L; Kuang M; Xu L; Li D; Cai J
Sci Rep; 2024 Apr; 14(1):9745. PubMed ID: 38679630
[TBL] [Abstract] [Full Text] [Related]
15. The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat liver Resection.
Gon H; Komatsu S; Omiya S; Kido M; Fukushima K; Urade T; Yoshida T; Arai K; Ishida J; Nanno Y; Tsugawa D; Yanagimoto H; Toyama H; Fukumoto T
Anticancer Res; 2024 May; 44(5):2031-2038. PubMed ID: 38677757
[TBL] [Abstract] [Full Text] [Related]
16. Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study.
Kimura K; Tanuma J; Kimura M; Imamura J; Yanase M; Ieiri I; Kurosaki M; Watanabe T; Endo T; Yotsuyanagi H; Gatanaga H
BMJ Open Gastroenterol; 2024 Apr; 11(1):. PubMed ID: 38677720
[TBL] [Abstract] [Full Text] [Related]
17. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract] [Full Text] [Related]
18. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
19. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
20. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
[TBL] [Abstract] [Full Text] [Related]
[Next]
